Immunomedics (IMMU) Reports In-Line Q4 Loss of 13c/Share

Immunomedics (NASDAQ: IMMU) reported Q4 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $1.13 million.

For earnings history and earnings-related data on Immunomedics (IMMU) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Reading (RDI) Tops Q2 EPS by 4c